everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...910111213141516171819...132133»
  • ||||||||||  Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap, Signifor (pasireotide) / Recordati
    Review, Journal:  The role of serotonin inhibition within the treatment of carcinoid syndrome. (Pubmed Central) -  Jul 12, 2023   
    Telotristat ethyl has been increasingly utilised for patients with symptoms despite taking somatostatin analogues...There are therefore numerous different therapies. This paper describes the pathophysiology and therapy of carcinoid syndrome.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  The treatment of aggressive prolactinomas with everolimus. (Pubmed Central) -  Jul 10, 2023   
    This paper describes the pathophysiology and therapy of carcinoid syndrome. Everolimus is an active agent in the treatment of prolactinomas that warrants further investigation.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Combination therapy, Metastases:  KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Jul 10, 2023   
    P3,  N=1069, Active, not recruiting, 
    Our study represents a further contribution to the literature on LPN and highlights the diagnostic value of PIK3CA mutation testing as surrogate tool in equivocal cases and in those lesions without associated macrodactyly, especially as the biopsy findings of this lesion are essentially nonspecific. Trial completion date: Oct 2024 --> Jul 2024
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments. (Pubmed Central) -  Jul 8, 2023   
    Several mTOR blockers have been tested in clinical trials, the most recent of which employed oral everolimus with encouraging results...The evidence of Vascular Endothelial Growth Factor (VEGF)- Vascular Endothelial Growth Factor (VEGFR) signaling hyperactivity in pediatric low-grade gliomas prompted the use of bevacizumab, an anti-VEGF monoclonal antibody, which was tested in children with low-grade gliomas or OPGs with good clinical results...Newer lines of research should be pursued with the goal of stabilizing or improving the vision, rather than reducing tumor volume. The growing understanding of the unique cellular and molecular characteristics of NF1-OPG, coupled with the recent publication of promising clinical studies, raise hope for a shift towards precision medicine and targeted therapies as a first-line treatment.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment. (Pubmed Central) -  Jul 7, 2023   
    According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.
  • ||||||||||  everolimus / Generic mfg.
    Verrucous venous malformation of the leg: a rare vascular anomaly () -  Jul 3, 2023 - Abstract #WCD2023WCD_6540;    
    KEY MESSAGE: VVM is rare, and have several differential diagnosis. Thus, clinical manifestation, histopathology, immunohistochemistry, ultrasound, and MRI plays an important role in making the diagnosis
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal, Metastases:  Emerging therapies for advanced insulinomas and glucagonomas. (Pubmed Central) -  Jun 21, 2023   
    When first-generation somatostatin analogues (SSAs) fail to control hypoglycemia syndrome, second-generation SSAs and everolimus have to be considered exploiting their hyperglycemic effect...PRRT seems to be an effective treatment when surgery and SSAs fail. The application of these therapeutic modalities has been shown to be efficacious in controlling the manifestations of the secretory syndrome and prolonging overall survival of patients suffering from these malignancies.
  • ||||||||||  everolimus / Generic mfg.
    Retrospective data, Journal:  Renal angiomyolipoma with tumor thrombi: Clinical analysis of 18 cases in a single-center experience. (Pubmed Central) -  Jun 19, 2023   
    Compared to CAML, EAML tended to be associated with a higher imaging misdiagnosis rate, and was more commonly associated with necrosis and a higher Ki-67 index. Surgery remains the prime treatment for nonmetastatic AML with TT; such cases have a relatively good prognosis despite the malignant potential.
  • ||||||||||  everolimus / Generic mfg.
    Preclinical, Journal, Combination therapy:  In Vitro and In Vivo Evaluation of Synergistic Effects of Everolimus in Combination with Antifungal Agents on Exophiala dermatitidis. (Pubmed Central) -  Jun 19, 2023   
    Clinically, the conventional treatment of E. dermatitidis is poor due to the long-term use of antifungal drugs. In this study, we have for the first time investigated the interaction and action mechanism of everolimus combined with itraconazole, voriconazole, posaconazole, and amphotericin B on E. dermatitidis in vitro and in vivo, which provided new ideas and direction for further exploring the mechanism of drug combination and clinical treatment of E. dermatitidis.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, PD(L)-1 Biomarker, IO biomarker:  Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. (Pubmed Central) -  Jun 19, 2023   
    Temozolomide is the recommended first-line chemotherapy, with response rates of about 40%...Bevacizumab has resulted in partial response (PR) in few patients; tyrosine kinase inhibitors and everolimus have generally not been useful...Considering that APT/PCs are rare, new therapies should preferably be evaluated in shared standardized protocols. Prognostic and predictive markers to guide treatment decisions are needed and are scope of ongoing research.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach. (Pubmed Central) -  Jun 19, 2023   
    The mammalian target of the rapamycin (mTOR) pathway regulates cell survival, metabolism, growth, and protein synthesis in response to upstream signals in both normal physiological and pathological situations, primarily in cancer...For the comparative analysis, 110 components of Cichorium intybus were employed and ten FDA-approved anticancer medicines, including everolimus, an mTOR inhibitor...Based on the results, taraxerone (98) revealed optimum binding affinities with mTOR, followed by stigmasterol (110) and rutin (104), which compared favorably to the control compounds. Subsequently, bioactive compounds derived from Cichorium intybus may serve as lead molecules for developing potent and effective mTOR inhibitors to treat breast cancer.
  • ||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma, quisinostat (JNJ 26481585) / ChemRar, Viriom, navitoclax (ABT 263) / AbbVie
    Journal:  Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target. (Pubmed Central) -  Jun 16, 2023   
    Importantly, the ferroptosis-related genes GPX4 and SLC7A11 are negatively correlated with the survival of UM patients (TCGA: n?=?80; Leiden University Medical Centre cohort: n?=?64), ferroptosis susceptibility is correlated with loss of BAP1, one of the key prognosticators for metastatic UM, and ferroptosis induction greatly reduced metastasis formation in the UM xenograft model. Collectively, we have established a patient-derived animal model for metastatic UM and identified ferroptosis induction as a possible therapeutic strategy for the treatment of UM patients.
  • ||||||||||  everolimus / Generic mfg.
    Journal, Immunogenic cell death:  mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death. (Pubmed Central) -  Jun 12, 2023   
    Using normal human colonic epithelial cells, EIF4E S209A knockin and BID knockout mice, we found that local inflammation and antitumor efficacy of Everolimus requires Myc-dependent induction of ER stress and apoptosis. These findings demonstrate mTOR and deregulated Myc as a selective vulnerability of mutant APC-driven intestinal tumorigenesis, whose inhibition disrupts metabolic and immune adaptation and reactivates immune surveillance necessary for long-term tumor control.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation. (Pubmed Central) -  Jun 12, 2023   
    These findings demonstrate mTOR and deregulated Myc as a selective vulnerability of mutant APC-driven intestinal tumorigenesis, whose inhibition disrupts metabolic and immune adaptation and reactivates immune surveillance necessary for long-term tumor control. These results suggest that the early introduction of mTOR benefits long-term kidney graft function and circulating activated Treg-cell expansion in KTRs.